Schizoaffective Disorders Completed Phase 3 Trials for Risperidone (DB00734)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00148083Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in SchizophreniaTreatment
NCT00132314Long-Acting Injectable Risperidone in the Treatment of SchizophreniaTreatment
NCT00159770Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic PatientsTreatment
NCT00283179Aripiprazole in the Treatment of Acutely Relapsed Patients With SchizophreniaTreatment
NCT00297388A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective DisorderTreatment
NCT00495118A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.Treatment
NCT00558298A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.Treatment
NCT00641745Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable SchizophreniaTreatment
NCT01888107Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective DisorderTreatment